Janus Henderson opens Global Life Sciences Strategy to UK clients

Managed by Andy Acker and Dan Lyons

clock • 1 min read

Janus Henderson has launched the Global Life Sciences Equity fund, allowing access to its US namesake strategy to UK investors.

The fund will take positions in firms addressing what it describes as "unmet medical needs" or "aimed at maintaining or improving quality of life". The strategy will aim to outperform the MSCI World Health Care index by at least 2% per annum over the course of a market cycle. Where are the opportunities to invest in 21st century healthcare? The established Janus Henderson Global Life Sciences strategy was founded over two decades ago and managers of the US-domiciled sister Global Life Sciences offering, Andy Acker and Dan Lyons, will both oversee the new UK-listed portfolio. Acker ...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Equities

Partner Content: Three Minutes With Federated Hermes Limited's Mark Sherlock

Partner Content: Three Minutes With Federated Hermes Limited's Mark Sherlock

What are the prospects for US SMID equities in 2024?

Federated Hermes Limited
clock 20 February 2024 • 1 min read
Partner Insight: Attractive yields but narrow spreads - The credit dilemma

Partner Insight: Attractive yields but narrow spreads - The credit dilemma

Arif Husain, Head of International Fixed Income and Chief Investment Officer, Fixed Income at T. Rowe Price
clock 14 February 2024 • 4 min read
Partner Insight: US SMID - Seven questions answered

Partner Insight: US SMID - Seven questions answered

After a bumpy 2023, small- and medium-sized US companies are now in a good place to outperform in 2024, argues fund manager Mark Sherlock.

Federated Hermes
clock 12 February 2024 • 6 min read
Trustpilot